InstalabAutoimmune Analyzer
Should you take a Autoimmune Analyzer test?
This test is most useful if any of these apply to you.
15 biomarkers included
- Thyroid1
- Anti-TPODetects antibodies against a thyroid enzyme, capturing the autoimmune thyroid disease that commonly travels with connective tissue disease.Why it mattersA positive result signals Hashimoto's thyroiditis, which clusters with lupus, Sjogren's, and rheumatoid arthritis.
- Autoimmunity14
- ANA ScreenThe broad entry test detecting antibodies against your own cell nuclei, flagging whether a systemic autoimmune process deserves closer investigation.Why it mattersA positive result opens the door to autoimmune disease but needs the specific antibodies to carry real meaning.
- DNA (DS) AntibodyTargets your own genetic material and is one of the most lupus-specific markers, tending to rise when lupus is active.Why it mattersA positive result strongly favors lupus and can signal active disease, especially kidney involvement.
- Chromatin AntibodyDetects reactivity to DNA wound around proteins, catching lupus-related activity even when the double-stranded DNA test reads negative.Why it mattersAdds lupus signal in some people who test negative for anti-dsDNA, seen in about 16% in one cohort.
- SS-A AntibodyTargets a nuclear protein tied most often to Sjogren's syndrome and lupus, and helps explain dry eyes and dry mouth.Why it mattersA positive result shifts the picture toward Sjogren's syndrome or lupus and matters for pregnancy planning.
- SS-B AntibodyUsually appears alongside SS-A and strengthens the case for Sjogren's syndrome when both are present.Why it mattersRarely positive alone, it reinforces a Sjogren's pattern rather than lupus.
- Anti-Sm AntibodyTargets the Smith nuclear protein and is highly specific for lupus, though it appears in only a minority of cases.Why it mattersA positive result is strong evidence for lupus, even though a negative one does not rule it out.
- RNP AntibodyTargets ribonucleoprotein and, when strongly positive by itself, is the defining marker of mixed connective tissue disease.Why it mattersHigh isolated levels point to mixed connective tissue disease rather than lupus alone.
- Centromere B AntibodyTargets the center of chromosomes and marks the limited form of systemic sclerosis, also called scleroderma.Why it mattersA positive result points to limited scleroderma and warrants watching for circulation and lung changes.
- Scleroderma AntibodyTargets an enzyme called topoisomerase and is specific for the diffuse form of systemic sclerosis.Why it mattersA positive result flags diffuse scleroderma, which carries higher risk of lung scarring.
- J-o1 AntibodyTargets an enzyme used in protein building and is the classic marker of antisynthetase syndrome, a form of autoimmune muscle disease (myositis).Why it mattersA positive result points to antisynthetase syndrome, with muscle inflammation and its associated lung involvement.
- Complement C3A blood immune protein used up when antibody-driven inflammation is active, so low levels track disease activity.Why it mattersA low level suggests active immune-complex disease and, in lupus, a higher risk of kidney flare.
- Complement C4A related immune protein that may fall even earlier than C3 in some cases of active autoimmune inflammation.Why it mattersA low level supports active lupus and may dip before a kidney flare becomes obvious.
- Rheumatoid Factor (RF)An antibody linked to rheumatoid arthritis that also appears in Sjogren's syndrome, adding evidence for a joint-centered overlap.Why it mattersA positive result raises suspicion for rheumatoid arthritis or Sjogren's overlap alongside the other findings.
- Ribosomal P AntibodyA highly specific lupus antibody that marks a particular subset of disease and rounds out the lupus-leaning markers.Why it mattersA positive result is strong evidence for lupus and has been linked to certain organ manifestations.
About Autoimmune Analyzer
Autoimmune diseases are notoriously hard to pin down. The same fatigue, joint pain, rashes, or dry eyes can point to lupus, Sjogren's syndrome, scleroderma, or none of them, and a single positive marker rarely settles the question.
This panel reads fifteen immune signals at once and looks for the pattern they form together. That pattern, not any one result, is what separates a meaningful autoimmune process from background noise.
What This Panel Reveals
The panel is built around one broad screen and several specific follow-up markers. The screen looks for antibodies aimed at your own cell nuclei, known as antinuclear antibodies (ANA). This test is very sensitive: in the meta-analysis used to build lupus classification criteria, it was positive in about 97.8% of people with the disease. On its own, though, it is not specific, so the rest of the panel exists to explain a positive screen.
One cluster of markers leans toward lupus (systemic lupus erythematosus). Antibodies to double-stranded DNA (your own genetic material), to the Smith protein, to chromatin (DNA wound around proteins), and to ribosomal P each point toward lupus with high specificity. A second cluster broadens the picture. Antibodies to ribonucleoprotein (called RNP) suggest mixed connective tissue disease, SS-A and SS-B suggest Sjogren's syndrome, centromere B and the scleroderma antibody (Scl-70) suggest systemic sclerosis, and Jo-1 suggests autoimmune muscle disease.
Two more pieces round out the story. Thyroid peroxidase antibodies (anti-TPO) capture autoimmune thyroid disease, which commonly travels with connective tissue disease, and rheumatoid factor (RF) adds evidence for a joint-centered or Sjogren's overlap. Finally, the immune proteins complement C3 and C4 fall when antibody-driven inflammation is actively consuming them, giving a read on how busy the immune system is right now rather than simply what it is targeting.
How to Read Your Results Together
The value of this panel is in the combinations. A positive ANA screen with specific antibodies underneath it means something very different from a positive screen with nothing else. Emerging evidence supports reading the markers as a group, and standardized interpretation frameworks are still evolving, so the patterns below are starting points for a conversation with a clinician, not verdicts.
| Pattern of results | What it may suggest |
|---|---|
| Positive screen, plus anti-dsDNA or Smith, with low C3 and C4 | A lupus pattern, especially if complement is low, which can signal active disease |
| Positive screen, plus SS-A and SS-B | A Sjogren's syndrome pattern, often with dry eyes and dry mouth, sometimes overlapping lupus |
| Positive screen, plus centromere B or the scleroderma antibody | A systemic sclerosis (scleroderma) pattern that warrants watching circulation and lungs |
| Strong RNP alone, without the lupus-specific markers | A mixed connective tissue disease pattern rather than lupus by itself |
Some numbers help calibrate expectations. The scleroderma-linked centromere antibody was positive in about 61% of limited systemic sclerosis in one study, higher than the 20 to 40% reported across most studies, so a negative result does not exclude disease. RNP is reported in roughly 95% of mixed connective tissue disease, and when it appears alone at high levels, about 74% of such people had that diagnosis in an early cohort. Anti-dsDNA is the mirror image: it shows up in only about half of lupus cases but almost never without it, reaching about 98% specificity in one assay comparison.
What to Do with Your Results
A fully negative panel in someone with mild, nonspecific symptoms is reassuring and usually means a systemic autoimmune disease is unlikely. A positive screen with specific antibodies, or low complement, is a reason to see a rheumatologist rather than a diagnosis by itself. Combined screening protocols reach around 93% sensitivity for connective tissue disease, which makes this a strong triage tool but not a final answer.
Different results point to different next steps. Low C3 and C4 alongside lupus-specific antibodies raise concern for kidney involvement, and a urine protein test and kidney panel are reasonable companions. A thyroid pattern from anti-TPO calls for thyroid hormone testing. The antibody profile also guides which specialist and which imaging or organ studies come next.
Serial tracking matters most for the moving parts. The specific antibodies tend to stay fairly stable once known, so they rarely need frequent repeats. Complement and anti-dsDNA fluctuate with activity, and in one analysis of pooled lupus trial data low C3 predicted impending kidney flares with close to three times the risk (hazard ratio 2.9). If you are actively managing a known condition, rechecking these every few months, and sooner around new symptoms, is a reasonable cadence.
When Results Can Be Misleading
The broad screen is the main source of confusion. A positive ANA is common in healthy people, especially women, older adults, and at low levels, and by itself it has poor predictive value. In one referral analysis, more than 90% of people sent to a specialist for an isolated positive screen turned out to have no ANA-associated rheumatic disease. As an entry test its specificity is only around 19.4%, which is exactly why the specific antibodies and complement in this panel carry the weight.
Timing and context also shift results. Antibodies can appear years before symptoms, infections and some medications can trigger a temporary positive screen, and assay methods differ between labs. A single snapshot is best read alongside your symptoms and, when needed, repeated over time.